BUZZ-Kymera rises as Gilead pays $45 million for experimental cancer drug

Reuters04-09 19:20
BUZZ-Kymera rises as <a href="https://laohu8.com/S/GILD">Gilead</a> pays $45 million for experimental cancer drug

** Shares of biotech firm Kymera Therapeutics KYMR.O rise 3% to $89.50 premarket

** Co says it will receive $45 million upfront from Gilead Sciences GILD.O to license KT-200, an experimental oral cancer drug

** KT-200 targets CDK2, a protein that helps tumors grow; the drug is designed to remove the protein entirely, which could improve effectiveness and reduce side effects - KYMR

** Co says the drug could help treat hard‑to‑treat cancers such as advanced breast cancer, where treatment options are limited

** Adds that Gilead gets global rights and will lead further development, aiming to start human studies in 2027

** Says Kymera could receive up to $750 million in total payments plus royalties if the drug is approved

** As of last close, stock up ~12% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment